Next Article in Journal
Designing an Effective Front-of-Package Warning Label for Food and Drinks High in Added Sugar, Sodium, or Saturated Fat in Colombia: An Online Experiment
Previous Article in Journal
Leukocyte Activation and Antioxidative Defense Are Interrelated and Moderately Modified by n-3 Polyunsaturated Fatty Acid-Enriched Eggs Consumption—Double-Blind Controlled Randomized Clinical Study
 
 
Article

Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial

1
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
2
Endocrinology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
3
Archer Daniels Midland Co-Biopolis, 46980 Valencia, Spain
4
Department of Endocrinology and Nutrition, Germans Trias i Pujol Research Institute, 08916 Barcelona, Spain
5
Service of Pediatric Endocrinology, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, 08208 Sabadell, Spain
6
CIBEROBN, Instituto de Salud Carlos III, 28029 Madrid, Spain
7
Child and Adolescent Psychiatry and Psychology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
8
CIBERDEM, Instituto de Salud Carlos III, 28029 Madrid, Spain
*
Author to whom correspondence should be addressed.
Nutrients 2020, 12(10), 3123; https://doi.org/10.3390/nu12103123
Received: 15 September 2020 / Revised: 6 October 2020 / Accepted: 9 October 2020 / Published: 13 October 2020
(This article belongs to the Section Prebiotics and Probiotics)
Prader–Willi syndrome (PWS) is a rare genetic disorder characterized by a wide range of clinical manifestations, including obesity, hyperphagia, and behavioral problems. Bifidobacterium animalis subsp. lactis strain BPL1 has been shown to improve central adiposity in adults with simple obesity. To evaluate BPL1′s effects in children with PWS, we performed a randomized crossover trial among 39 patients (mean age 10.4 years). Participants were randomized to placebo–BPL1 (n = 19) or BPL1–placebo (n = 20) sequences and underwent a 12-week period with placebo/BPL1 treatments, a 12-week washout period, and a 12-week period with the crossover treatment. Thirty-five subjects completed the study. The main outcome was changes in adiposity, measured by dual-energy X-ray absorptiometry. Secondary outcomes included lipid and glucose metabolism, hyperphagia, and mental health symptoms. Generalized linear modeling was applied to assess differences between treatments. While BPL1 did not modify total fat mass compared to placebo, BPL1 decreased abdominal adiposity in a subgroup of patients older than 4.5 years (n = 28). BPL1 improved fasting insulin concentration and insulin sensitivity. Furthermore, we observed modest improvements in some mental health symptoms. A follow-up trial with a longer treatment period is warranted to determine whether BPL1 supplementation can provide a long-term therapeutic approach for children with PWS (ClinicalTrials.gov NCT03548480). View Full-Text
Keywords: obesity; Prader–Willi syndrome; insulin sensitivity; hyperphagia; gut microbiota; probiotic supplementation; mental health obesity; Prader–Willi syndrome; insulin sensitivity; hyperphagia; gut microbiota; probiotic supplementation; mental health
Show Figures

Figure 1

MDPI and ACS Style

Amat-Bou, M.; Garcia-Ribera, S.; Climent, E.; Piquer-Garcia, I.; Corripio, R.; Sanchez-Infantes, D.; Villalta, L.; Elias, M.; Jiménez-Chillarón, J.C.; Chenoll, E.; Ramón, D.; Ibañez, L.; Ramon-Krauel, M.; Lerin, C. Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial. Nutrients 2020, 12, 3123. https://doi.org/10.3390/nu12103123

AMA Style

Amat-Bou M, Garcia-Ribera S, Climent E, Piquer-Garcia I, Corripio R, Sanchez-Infantes D, Villalta L, Elias M, Jiménez-Chillarón JC, Chenoll E, Ramón D, Ibañez L, Ramon-Krauel M, Lerin C. Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial. Nutrients. 2020; 12(10):3123. https://doi.org/10.3390/nu12103123

Chicago/Turabian Style

Amat-Bou, Montse, Sonika Garcia-Ribera, Eric Climent, Irene Piquer-Garcia, Raquel Corripio, David Sanchez-Infantes, Laia Villalta, Maria Elias, Josep C. Jiménez-Chillarón, Empar Chenoll, Daniel Ramón, Lourdes Ibañez, Marta Ramon-Krauel, and Carles Lerin. 2020. "Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial" Nutrients 12, no. 10: 3123. https://doi.org/10.3390/nu12103123

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop